EGFR and neoplasm: In addition, G31P-mediated CXCR1/2 inhibition disrupts the pathological feedback loop in the tumor microenvironment, where ELR+ CXC chemokines (CXCL1/8) activate CXCL8, leading to EGFR transactivation and sustained inflammatory signaling.